| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8789190 | Practical Radiation Oncology | 2018 | 30 Pages |
Abstract
We investigated the impact of 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) on radiation therapy planning for patients diagnosed with glioblastoma (GBM) and a suspected nonenhancing tumor compared with standard magnetic resonance imaging. We performed volumetric analyses between clinical target volumes and respective biological target volumes using Wilcoxon signed-rank tests. FET-PET may help improve delineation of GBM in cases with a suspected nonenhancing component and reduce the risk of potential geographical miss.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Aimee R. BSc (Med), MBBS, FRACP, Dasantha BSc (Med), MBBS, FRANZCR, Edward MBChB, FRANZCR, Geoffrey P. MBBS, FRACP, Dale L. PhD, FIPEM, FACPSEM, Paul J. MBBS, FRACP, Mustafa MBChB, MD, MRCP, FRACP, Allison MBBS, FRANZCR, Helen R. MBBS, FRACP,